ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL™, a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor advancing into clinical development. ContraVir is also developing Valnivudine™, now in Phase 3 trials, for the treatment of herpes zoster and shingles associated pain known as post-herpetic neuralgia (PHN).
A Shingles Treatment with Best in Class Potential
Our lead candidate is Valnivudine™, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. Valnivudine™ is well-tolerated and has been shown to reduce PHN pain in Phase 2 trials.